title: Developments in urologic oncology 'OncoForum': The best of 2014.
abstract: OBJECTIVE
  To review the latest evidence on the oncologic urology of prostate, renal and bladder tumors, analyzing their impact on daily clinical practice and the future medium to long-term regimens.
  
  
  METHODS
  We review the abstracts on prostate, renal and bladder cancer presented at the 2014 congresses (European Association of Urology, American Urological Association, American Society of Clinical Oncology and American Society for Radiation Oncology) that received the best evaluations by the OncoForum committee.
  
  
  RESULTS
  The committee considered the following messages important: cytoreductive nephrectomy followed by treatment with a tyrosine-kinase inhibitor can significantly increase the overall survival of patients with metastatic renal cancer; for advanced bladder cancer, early adjuvant chemotherapy after cystectomy is preferable because it significantly increases progression-free survival; and several studies have shown that multiparametric magnetic resonance imaging and fusion imaging improve the diagnosis of prostate cancer and provide greater possibilities for placing patients in the appropriate risk group in order to offer them the best treatment possible. The results of the PREVAIL study have demonstrated the efficacy of enzalutamide on the overall survival of men with castration-resistant prostate cancer and metastases, with no prior chemotherapy. The study also demonstrated the drug's favorable safety profile.
  
  
  CONCLUSIONS
  Progress is continuing in renal and bladder cancer, improving the approach and clinical results with current therapeutic options. There is constant progress in castration-resistant prostate cancer; in 2014, prechemotherapy treatments were consolidated.
authors.affiliation: Servicio de Urología, Hospital Universitario de Salamanca, Salamanca, España. Electronic address: fgveiga@telefonica.net.
authors.forename: F
authors.initials: F
authors.lastname: Gómez-Veiga
authors.affiliation: Servicio de Urología, Hospital Clínic, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: Alcaraz-Asensio
authors.affiliation: Servicio de Urología, Hospital Ramón y Cajal, Madrid, España.
authors.forename: J
authors.initials: J
authors.lastname: Burgos-Revilla
authors.affiliation: Servicio de Urología, Hospital Virgen de las Nieves, Granada, España.
authors.forename: J
authors.initials: J
authors.lastname: Cózar-Olmo
mesh_terms: D001549:Benzamides; D017024:Chemotherapy, Adjuvant / Q000639:trends; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003226:Congresses as Topic; D005060:Europe; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000639:trends*; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D018787:Radiation Oncology / Q000639:trends*; D012955:Societies, Medical; D014481:United States; D014571:Urologic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D013520:Urologic Surgical Procedures / Q000639:trends; D014572:Urology / Q000639:trends*
chemical_list: D001549:Benzamides; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D010669:Phenylthiohydantoin; C540278:enzalutamide
keywords: Bladder cancer; Cáncer de próstata; Cáncer de vejiga; Cáncer renal; Onco-urología; Oncologic urology; Prostate cancer; Renal cancer; Uro-oncología; Urologic oncology